Novo Nordisk Manufacturing Kalundborg have more than 50 years of expertise in large-scale biotech manufacturing. 4,500 employees produce half of the world’s insulin, GLP-1, and several biopharmaceutical products, reaching more than 40 million people living with diabetes and other chronic diseases.
From 2022-2029 Novo Nordisk invest 60 billion DKK to expand existing facilities in Kalundborg, for the current and future portfolio within serious chronic diseases. This will establish additional capacity across the entire global value chain from manufacturing of active pharmaceutical ingredients (API) to packaging, with the vast majority being invested in API capacity. With the investment, more than 1,200 new jobs will be created.
Now is your opportunity to be part of our exciting journey and help establish the future factories of Novo Nordisk. The new facilities include state-of-the-art production technologies, which will be bridged with our more than 50 years of experience in biomanufacturing.
https://www.novonordisk.com/